<DOC>
	<DOCNO>NCT00502567</DOCNO>
	<brief_summary>A multicentre , 2-part study ass safety tolerability daily oral dos AZD2171 administer various anticancer regimen ( part A ) confirm tolerability combination FOLFOX ( part B ) .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability PK AZD2171 Chemotherapy Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologically confirm metastatic cancer amenable surgery radiation therapy curative intent measurable lesion CT techniques accord RECIST Inadequate bone marrow reserve history poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>AZD2171</keyword>
	<keyword>Phase I</keyword>
</DOC>